Advertisement

Organisation › Details
Triastek Inc. (CN)
Global leader in 3D printing pharmaceuticals, Pioneer of new digital pharmaceutical processes Founded in July 2015, Triastek is dedicated to the mission of "revolutionizing the pharmaceutical industry, unlocking the next generation of medicine and benefitting patients worldwide." We have created the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical process, transforming the delivery, development, and production of medicines through digital product development and continuous manufacturing. Leveraging our proprietary 3D printing pharmaceutical technology, we design and develop transformative medicines for patients. Through collaboration with global pharmaceutical companies, we tackle challenging formulation problems, accelerating the development of new drug products and improving the quality of pharmaceuticals. Our vision is to become the world's most influential intelligent pharmaceutical enterprise. About Triastek's Systematic Technology and Applications Triastek created the Melt Extrusion Deposition (MED®) 3D printing pharmaceutical technology, developed and constructed a new 3D printing drug technology system, covering new processes/equipment, new platforms, and new products, providing end-to-end technical solutions for drug products including design, development, manufacturing, and commercial supply. Leveraging the MED® technology, Triastek has built three pharmaceutical processes, which named MED® process, Melt Extrusion Deposition plus Micro-Injection Molding (MED&MIM) process and Melt Extrusion Deposition plus Semi-Solid Extrusion (MED&SSE) process. Triastek has also developed five 3D microstructure drug delivery technology platforms: Modified Release, Solubility Enhancement, Colon Targeting, Gastric Retention, and Oral Peptide, and developed multiple 3D printed drug product pipelines. *
![]() |
Start | 2015-07-01 established |
Group | Triastek (Group) | |
![]() |
Industry | 3D printing of drugs |
Industry 2 | oral drug delivery technology | |
![]() |
Person | Cheng, Senping (Triastek 202407 CEO + Founder) |
Person 2 | Zhang, Yulian (Triastek 202407 VP of Global Business Development) | |
![]() |
Region | Nanjing |
Country | China | |
City | 211100 Nanjing, Jiangsu province | |
Address record changed: 2024-07-31 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: Triastek, Inc.. (7/23/24). "Press Release: Triastek Announces Research Collaboration and Platform Technology License Agreement with BioNTech to Advance 3D Printed Oral RNA Therapeutics". Nanjing. | ||
Record changed: 2024-09-22 |
Advertisement

More documents for Triastek (Group)
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top